From molecular data to clinical intelligence
Precision oncology is the practice of using detailed information about a specific tumour — molecular, pathological and clinical — together with the scientific evidence, to inform decisions about that particular case.
An integration problem
Precision oncology brings four kinds of information into contact with one another: the clinical picture, the pathology, the molecular data, and the evidence base.
Each is routinely available. What is less routine is holding them together — reading a molecular finding in the light of the disease course, the treatment already given and the actual strength of the supporting evidence.
That integration is the work. It is not a separate kind of treatment, and it does not introduce new therapies. It changes how the available options are compared.
Four things to be clear about
- <strong>A guarantee of a treatment.</strong> A molecular finding may suggest an option. It does not promise one exists, is available, or will work.
- <strong>A replacement for a treating oncologist.</strong> This work supports the treating team. It does not take over clinical care, and does not involve prescribing or administering therapy.
- <strong>A claim that every mutation is actionable.</strong> Most detected alterations have no therapeutic implication. Saying so plainly is part of a competent interpretation.
- <strong>A substitute for urgent medical care.</strong> Acute symptoms need acute assessment. Nothing here is a route for time-critical clinical decisions.
Seven stages
Every case is worked through in the same order. The sequence matters: molecular findings read before the clinical context is established tend to be over-weighted, and evidence assessed before the molecular picture is settled tends to answer the wrong question.
From cancer data to a clinical decision
- 01 Clinical context Who the patient is and what the disease has done
- 02 Pathology Tissue diagnosis, grade, immunohistochemistry
- 03 Molecular data Somatic, germline, circulating
- 04 Computation Annotation, tiering, modelling
- 05 Evidence What the literature actually supports
- 06 Decision Where it changes something — or does not
Each stage constrains the next. A molecular finding read before the clinical context is established is routinely over-weighted.
-
Clinical context
Who the patient is, what the disease has done so far, what has been tried and how it was tolerated.
-
Pathology
The tissue diagnosis, its grade and architecture, immunohistochemistry, and whether the diagnosis itself is secure.
-
Molecular profiling
Somatic and germline findings, with attention to what the assay could and could not have detected.
-
Computational interpretation
Annotation, tiering and analysis — the methods that determine which conclusions the data actually supports.
-
Evidence synthesis
What the literature supports for this configuration, at what strength, and where it is thin or absent.
-
Strategy discussion
The analysis discussed as a set of options and questions, with the treating team, rather than issued as an instruction.
-
Monitoring and longitudinal consideration
How the case should be followed, and what molecular change over time would mean.
Not every finding carries the same weight
- I Therapeutic, in this disease Randomised or regulatory-grade evidence for this alteration in this cancer.
- II Therapeutic, another disease Strong evidence, but established in a different tumour type.
- III Clinical trial eligible Supports enrolment rather than a licensed treatment decision.
- IV Preclinical or case report Biologically plausible; the clinical evidence is thin or absent.
A molecular report lists findings. Tiering says which of them a decision can actually rest on — and the bar length is the strength of that support.
A cancer case is a trajectory, not a snapshot
- Month 0 Diagnosis Biopsy, pathology, staging
- Month 1 Molecular profile Comprehensive genomic profiling
- Month 2 First-line therapy Treatment begins
- Month 8 Response ctDNA falls; imaging confirms
- Month 14 Molecular change ctDNA rises before imaging changes
- Month 16 Progression Radiological progression confirmed
- Month 17 Re-profiling Resistance alteration identified
Molecular change frequently precedes clinical change. Reading a case as a sequence rather than a single timepoint is what makes that visible.
How this work is delivered
Different questions need different depths of review. These are the routes most often used; the full list covers ten.
Precision Oncology Consultation
Molecular Report Review
Cancer Second Opinion
Precision Oncology Analysis & Strategy
Molecular Tumour Board Review
Clinical Trial Matching
Specific areas
Three areas that come up often enough in complex cases to warrant their own treatment.
Molecular Tumour Board
Liquid Biopsy & ctDNA
Cancer Genetics & Hereditary Risk
Start a case review
Patients and families begin with a review request. Clinicians refer through the structured referral pathway.